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Aims: Progression of chronic kidney disease (CKD) in patients with diabetes is a growing problem. Diabetes is
associated with elevated endothelin-1 (ET-1) and enhanced renal expression of the endothelin A receptor
(ETAR). Atrasentan, a highly selective ETAR antagonist, reduces albuminuria in patients with DN.
Key methods: This was a randomized, double-blind trial of subjects with type 2 diabetes on renin–angiotensin sys-
tem (RAS) inhibitors having eGFR >20ml/min, and urine albumin-to-creatinine ratio (UACR) of 100–3000 mg/g,
who were allocated to placebo, 0.25, 0.75 or 1.75 mg atrasentan.
Key ﬁndings: UACR was reduced in the 0.75 mg and 1.75 mg groups (42% and 35% vs placebo, Pb0.011) over the
8 week treatment period. Edema was reported in 21 subjects: 62% of edema events emerged during the ﬁrst
4 weeks. There were no signiﬁcant changes in serum hsCRP, IL-6, NT-pro-BNP, ET-1, urine TGFb or MCP-1.
Urine NGAL was reduced 24% in the 1.75 mg group (P=0.044). Hispanic subjects (58% of total) tended to
have greater UACR reductions than non-Hispanics (0.75 mg dose: Hispanic: 41–60%; non-Hispanic: 18–37%;
P=0.012 and 0.048 vs placebo, respectively)without different rates of edema.MeanUACR reduction in subjects
receivingmaximumdoses of RAS inhibitors (38%)was 32% and 35% in the 0.75 and 1.75 mg groups, respectively,
and similar to overall UACR changes.
Signiﬁcance: Edema formation was dose-dependent and occurred early. The decrease in urine NGAL warrants
further study in renal tubular disease attenuation. UACR responses based on ethnicity need further characteri-
zation. Results suggest atrasentan may have additive effects to RAS inhibition in treatment of DN.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
The progression of chronic kidney disease (CKD) in patients with
long-standing diabetes is a growing problem owing to the global
rise in diabetes incidence and to the lack of a therapeutic agent that
prevents progression. The failure of inhibitors of the RAS to halt dis-
ease activity emphasizes the complexity of its pathogenesis and indi-
cates the likelihood that multiple agents will ultimately be required
for the proper treatment of diabetic nephropathy (DN).
Diabetes is associated with elevated blood and kidney levels of
endothelin-1 (ET-1) and enhanced renal expression of the endothelin A
receptor (ETAR) (Minchenko et al., 2003; Kakizawa et al., 2004; Kohan,
2010). Pre-clinical studies in diabetic models indicate that ETAR over-
activity contributes directly to podocyte and mesangial cell dysfunc-
tion and that antagonists of the ETAR attenuate proteinuria andResearch and Development,
, IL 60064, United States. Tel.:
dress).
Y-NC-ND license.glomerulosclerosis (Ortmann et al., 2004; Neuhofer and Pittrow, 2009)
particularly in combinationwith RAS inhibitors (Morigi et al., 2005). Con-
comitant ETBR antagonism, however, potentially complicates long-term
treatment because of the importance of normal ETBR function to prevent
ﬂuid retention (Kohan, 2009). This concernwas recently exposed in a piv-
otal clinical trial in patients with diabetes who received the ET receptor
antagonist, avosentan, where excessive reports of ﬂuid retention, heart
failure and death were reported (Mann et al., 2010).
Atrasentan is a small molecule designed to be a highly selective an-
tagonist of the ETAR (Opgenorth et al., 1996) that has shown recent
promise in patients with DN. Recently published Phase 2 results indi-
cate that low doses of atrasentan substantially reduce urinary albumin
excretion in patients with diabetes when added to stable RAS inhibitor
therapy, with minimal concern for ﬂuid retention (Kohan et al., 2011a).
The purpose of the present post-hoc analyses of these data was to fur-
ther characterize the edema events that resulted from atrasentan ther-
apy, to determine whether biomarkers were affected by treatment and
to assess potential differences for efﬁcacy and safety among different
ethnicities. While the Phase 2 study design did not require maximum
RAS inhibition for entry, approximately 37% of enrolled subjects were
Table 1
Least squares mean change in uNGAL from baseline to week 8.
Treatment group Least squares mean (SE) % change from baseline P-value
Placebo 0.08 (0.14) +8
Atrasentan 0.25 mg −0.17 (0.15) −15 0.127
Atrasentan 0.75 mg −0.15 (0.14) −14 0.138
Atrasentan 1.75 mg −0.28 (0.15) −24 0.044
740 D.L. Andress et al. / Life Sciences 91 (2012) 739–742receiving maximum anti-RAS therapy and this report will further char-
acterize their response to atrasentan in comparison to those with less
than maximum RAS inhibition.
Methods
This was a randomized, double blind trial of subjects with type 2
diabetes on stable doses of RAS inhibitors having an eGFR >20 mL/
min/1.73 m2 and albuminuria of 100–3000 mg/g creatinine (UACR),
who were allocated to placebo, 0.25 mg, 0.75 mg, or 1.75 mg of atra-
sentan daily for 8 weeks. The protocol was later amended to have
serum NT-pro-BNP >500 pg/mL as an exclusion. Subjects were fol-
lowed at weekly intervals for adverse event reporting, physical exam-
inations and for collection of blood and urine specimens during the
8 week treatment period and again 30 days after discontinuation of
study drug. Subjects were not permitted to alter their dose of RAS
inhibitor during the 8 week treatment period. The primary endpoint
was a weekly change in UACR from baseline using a repeated mea-
sures analysis method. Peripheral edema was deﬁned as mild if
present on examination but asymptomatic and subject will to contin-
ue study medication, moderate if edema was present and was symp-
tomatic but the subjects was willing to continue the study medication
and severe if the edema was symptomatic and the subject was
unwilling to continue receiving study drug or the subject had an ad-
verse event of pulmonary edema or congestive heart failure. Bio-
markers were measured real-time in a central lab at baseline and
at end-of treatment and included serummeasurements of high sensi-
tive C-reactive protein (hsCRP) and interleukin-6 (IL-6), and urine
measurements of monocyte chemo-attractant protein-1 (uMCP-1)
and transforming growth factor-B (uTGFb). Urinary neutrophil
gelatinase-associated lipocalin (uNGAL) was also measured to detect
possible renal tubular injury (Bolignano et al., 2009). Serum NT-pro-
BNP and endothelin-1 (ET-1) levels were measured at each visit.
Statistical analyses were applied to the intention to treat (ITT) popu-
lation as described previously (Kohan et al., 2011a). Baseline contin-
uous variables were analyzed using one-way ANOVA and categorical
variables were analyzed using Fisher's exact test. The primary efﬁcacy
measure was change in baseline to each post-baseline observation in
log-transformed UACR during treatment using a repeated measures
model and the results are presented as the inverse transformation
as percent of geometric mean change.
Results
General
Therewere 89 subjects whowere randomized: 23 to placebo and 22
to each atrasentan dose group. Baseline demographics and biochemis-
tries were similar among the groups (Kohan et al., 2011a).The mean
age was 63+/−10 years, 69% were male, and 87% were Caucasian.
UACR was signiﬁcantly reduced in the groups receiving 0.75 mg and
1.75 mg QD (42% and 35% vs placebo, Pb0.011 by repeated measures,
respectively) and returned to baseline levels after 30 days off study
drug, as previously reported (Kohan et al., 2011a).
Edema
There were 21 subjects who reported adverse events of treatment-
emergent edema, deﬁned as “peripheral edema” and “edema”. Of
those 21 subjects, 13 were taking diuretics at baseline. The incidence
of mild or moderate edema was: placebo: 2/23, 0.25 mg: 4/22,
0.75 mg: 5/22, and 1.75 mg: 10/22; none reported severe edema.
Treatment-emergent edema was reported in 62% during the ﬁrst
4 weeks and 2 subjects were discontinued: one in the 1.75 mg group
for acute angioedema and one in the 0.75 mg group for congestive
heart failure (baseline NT-pro-BNP, 4400 pg/ml). Of the 21 subjectswith edema, 6 resolved by treatment end, 9 resolved during the
30 day follow-up after treatment, and 5 had continued edema to the
end of the study. Seven subjects started diuretics during the study. Vari-
ables associated with a higher risk of edema by logistic regression were
treatment group (1.75 mg, OR=17.9, P=0.005) and baseline UACR
(≤300 or >300 mg/g, OR=6.1, P=0.012).
Biomarkers
CRP, IL-6, uMCP-1 and uTGFb are markers of inﬂammation and
uNGAL is a marker of renal tubular injury. Baseline levels of CRP, IL6,
uMCP-1 and uTGFb were not different among the treatment groups. Fol-
lowing treatment, therewere no statistically signiﬁcant differences in the
serum and urine inﬂammatory markers between the treatment groups
and placebo. Similarly, there were no signiﬁcant changes in serum NT-
pro-BNP (P=0.63) or ET-1 (P≥0.27) among the treatment groups.
The geometric mean uNGAL values at baseline were 19, 27, 29 and
28 ng/ml for placebo, 0.25, 0.75 and 1.75 mg atrasentan, respectively.
Overall uNGAL values from baseline to Week 8 rose 8% in the placebo
group and fell 15% (P=0.127), 14% (P=0.138) and 24% (P=0.044)
in the 0.25 mg, 0.75 mg and 1.75 mg atrasentan groups, respectively.
The least squaresmean differences are given in Table 1. After treatment
withdrawal, NGAL was reduced 11% in the placebo group and rose to
41%, 63% and 13% in the 0.25 mg, 0.75 mg, and 1.75 mg atrasentan
groups, respectively (Fig. 1). Atrasentan treatment also reduced UACR,
with the greatest reduction of −43% and −36% in the 0.75 and
1.75 mg dose groups compared with−11% in placebo
Ethnic differences
There were 52 Hispanic (58%) and 37 non-Hispanic subjects
(42%). Baseline characteristics were similar between Hispanics and
non-Hispanics except that systolic blood pressure (SBP) and HbA1c
were higher in Hispanic subjects (Pb0.05). The Hispanic and non-
Hispanic groups had clinically relevant reductions in UACR in the
0.75 and 1.75 mg but not the 0.25 mg dosing groups (Table 2). The
mean change in UACR reduction trended higher in Hispanics when
comparing each weekly visit to baseline: range of % UACR reduction
in Hispanics for 0.75 mg (41–60%, P=0.012 vs placebo) and
1.75 mg (21–50%, P=0.077 vs placebo), non-Hispanics for 0.75 mg
(18–37%, P=0.048 vs placebo) and 1.75 mg (22–34%, P=0.034 vs
placebo) (Fig. 2). Hispanic subjects had a non-signiﬁcant reduction
in SBP with the highest dose of atrasentan and rates of peripheral
edema were similar between Hispanic and non-Hispanic subjects.
Maximum RAS inhibition
There were 33 subjects taking maximum RAS inhibitors (37%).
Baseline demographics were similar between the groups. Treatment-
by-subgroup interaction was tested using the ITT population. The
treatment-by-subgroup interaction for change from baseline to ﬁnal
log UACRwas not signiﬁcant (P=0.816), suggesting that subjects taking
themaximumRAS inhibitor dose and those taking lower thanmaximally
recommended responded similarly to atrasentan. (Table 3).
The longitudinal assessment of UACR in subjects receiving maximal
RAS inhibition is shown in Fig. 3. The 0.75 mg and 1.75 mg groups
showed similar reductions in UACR after 4 weeks of treatment which
Fig. 1. Percent change in geometric mean uNGAL from baseline to week 8 and from last
on treatment visit to 30 days post treatment.
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and non-Hispanic subjects.
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UACR changes reported previously for the whole group (Kohan et al.,
2011a). The change from baseline UACR is similar in subjects receiving
sub-maximum levels of RAS inhibitors, as was previously described
(Kohan et al., 2011a).
Discussion
This post-hoc analysis provides additional insights into the re-
sponse of patients with diabetes who receive a combination of RAS
inhibition and low dose atrasentan. Details about edema formation,
biomarker response and population differences for ethnicity and ex-
tent of RAS inhibition were not reported in the original publication
(Kohan et al., 2011a).
Edema occurrence with atrasentan was dose-dependent, mostly
mild or moderate and usually appeared within the ﬁrst 4 weeks of
treatment. Less than a third of subjects initiated diuretics during treat-
ment and 71% resolved their edema before the end of study. These
short-term results suggest that with appropriate patient selection (no
history of heart failure, NT-pro-BNPb500), low dose atrasentan may
be safe for long-term clinical trials. The ﬁnding that NT-pro-BNP levels
were not increasedwith atrasentan exposure is consistentwith the clin-
ical safety proﬁle of low dose treatment in a population that is prone to
heart failure.
The observation that selected biomarkers of inﬂammation were not
affected by atrasentan therapy suggests that other biomarkers need to
be evaluated to elucidate possible mechanisms of action. Alternatively,
atrasentanmay reduce UACR on a short-term basis mainly by hemody-
namic factors that reduce glomerular ﬁltration fraction (Dhaun et al.,
2011). Consideration should be given to a full range analysis of availableTable 2
UACR and systolic blood pressure response to atrasentan in Hispanic and non-Hispanic
subjects.
Atrasentan
PBO 0.25 mg 0.75 mg 1.75 mg
N Hispanic 13 12 14 11
N Non-Hispanic 10 8 8 10
UACR, % reduction from BL (range)
Hispanic 20 (0–22) 16 (5–33) 54* (41–60) 40* (21–50)
Non-Hispanic 0 (0–8) 28 (17–29) 30† (18–37) 26 (22–34)
SBP change from BL to week 8 minus PBO, mm Hg
Hispanic +5.3 −9.3 −11.3
Non-Hispanic −10.9 −8.9 −6.2
*Pb0.05, †Pb0.100 compared with PBO.biomarkers in future long-term studies. Notably, the lack of a change in
serum ET-1 levels suggests that ETB receptor blockade is minimal or
non-existent since ETB receptors function in part to remove ET-1 from
the circulation (Kohan et al., 2011b).
The ﬁnding that a signiﬁcant reduction in urinary NGAL was ob-
served during atrasentan treatment is novel but needs to be con-
ﬁrmed in a larger trial for a more prolonged exposure. While the
results are suggestive of a dose response effect they do not parallel
the UACR response, suggesting that any putative effect of atrasentan
to ameliorate renal tubular injury may be independent of its pre-
sumed direct effect on glomerular hemodynamics. Notably, the
30 day off-treatment responses (Fig. 1) are consistently opposite to
those seen during the treatment period suggesting that there may
have been a true drug effect.
Hispanic patients with diabetes may experience a greater reduc-
tion in UACR compared to non-Hispanics in response to atrasentan
(Table 2) though the small sample size requires that this observation
be conﬁrmed in a larger study. While the reason for this potential dif-
ference is not apparent in this study, ethnic differences have been
reported in other studies of CKD patients where treatment that im-
proves glomerular hemodynamics, e.g. RAS inhibitors, have been
used (Chan et al., 2004). Future studies with larger populations
among all ethnic groups should be evaluated for possible differential
responses in efﬁcacy and side-effect proﬁles.
Current guidelines suggest that patients with diabetes and residu-
al albuminuria on less than maximum RAS inhibitor therapy should
have their dose up-titrated to the highest tolerated labeled dose.
However, challenges to achieving maximum RAS inhibitor therapy,
such as hyperkalemia or hypotension, result in a sizable minority
who are chronically maintained on less than the maximum dose. Im-
portantly, patients in this study who were receiving the maximum la-
beled RAS inhibitor dose appeared to have a similar beneﬁcialTable 3
Response to atrasentan among patients on maximum RAS inhibition.
Change from BL to
week 8
Atrasentan
PBO 0.25 mg 0.75 mg 1.75 mg
Mean (SE) (N=9) (N=5) (N=8) (N=11)
UACR (% change) +5% −27% −32%a −35%b
SBP (mm Hg) +0.8 (4.6) −1.4(6.4) −12.2 (5.0) −6.5 (4.2)
eGFR (mL/min/BSA) +3.2 (2.6) +4.1 (3.9) −5.3 (2.8) −0.2 (2.4)
N=4
Subjects with a 40%
reduction UACR
11% 40% 63%c 36%d
Edema (% of subjects) 11% 40% 13% 58%
P-values vs PBO.
a 0.134.
b 0.087.
c 0.050.
d 0.319.
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Fig. 3. Longitudinal changes in UACR in subjects receiving maximum RAS inhibition.
742 D.L. Andress et al. / Life Sciences 91 (2012) 739–742response (~ 40% reduction in UACR) when compared to those pa-
tients receiving less than maximal RAS inhibition. This suggests that
there may be different mechanisms of action for these two compound
classes and their combination may result in additive or possibly syn-
ergistic effects. In this regard, a recent pre-clinical study demonstrat-
ed a potential regression of glomerular injury in a diabetic model
when an ETA receptor antagonist was added to angiotensin convert-
ing enzyme inhibitor therapy (Gagliardini et al., 2009).
Conclusion
The highly selective ETA receptor antagonist, atrasentan, has
shown efﬁcacy and tolerability when added to RAS inhibitor therapy
in a short-term trial for albuminuria reduction in patients with type
2 diabetes. Ongoing Phase 2b studies will complete the dose ranging
evaluation for this compound to identify the optimal long-term
dose for the Phase 3 pivotal trial.
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